Artrosan (meloxicam) is a prescription medicine commonly used to provide supportive symptomatic relief for conditions primarily driven by inflammation and pain. It focuses on easing symptom burden, which may assist with improving day-to-day comfort and maintaining functional stability.

The medication is indicated for the relief of the signs and symptoms associated with chronic inflammatory joint conditions.

Therapeutic Focus and Relief

Artrosan is relevant for managing conditions characterized by persistent joint pathology, specifically Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in addressing the symptoms of Juvenile Idiopathic Arthritis in specific pediatric patients.

The medication helps address symptom clusters involving joint swelling, tenderness, and stiffness, including rigidity that may fluctuate. In clinical settings that involve acute or unstable symptom patterns, such as managing acute post-operative pain, Artrosan contributes to improved day-to-day comfort and supports the patient during episodes of heightened discomfort.

“The application of Artrosan is relevant for easing symptoms that create noticeable functional strain.”

Quick Fact: Relief for Inflammatory Pain
Artrosan is used when symptoms interfere with daily functioning, providing supportive relief that may assist with maintaining functional stability.

Regulatory References

1. DailyMed Label for Meloxicam

Official Contraindications (Must Not Use)

Artrosan is strictly prohibited for individuals with known hypersensitivity to meloxicam or a history of allergic reactions (such as asthma, hives, or rhinitis) to aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID). Use is also contraindicated in patients who have undergone Coronary Artery Bypass Graft (CABG) surgery.

The medicine must not be used by patients with active or a history of recurrent gastrointestinal bleeding or peptic ulceration, severely impaired liver function, or severe, non-dialysed renal failure. Use is also prohibited in cases of severe, uncontrolled heart failure.

Eligibility Restrictions and Age-Group Rules

Age and Pediatric Use: Artrosan is indicated for adults and is approved for Juvenile Idiopathic Arthritis in specific pediatric patients (ge 2 years), but it is generally contraindicated for children under 16 years of age (varies by formulation/region).

Geriatric Use: Elderly patients (ge 65 years) require caution and should typically start with the lowest effective dose.

Pregnancy and Lactation: Use is strictly avoided in the third trimester of pregnancy (approx 30 weeks gestation and later) due to fetal risk. Use is not recommended for women attempting to conceive due to potential impacts on fertility. Patients on hemodialysis are restricted to a specific maximum daily dose.

Artrosan's official interaction profile is formally defined by pharmacodynamic and pharmacokinetic patterns documented in regulatory prescribing information. The co-administration of Artrosan with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including analgesic doses of aspirin, is generally not recommended due to an officially documented increased risk of serious gastrointestinal adverse events.

Restrictions and Contraindications

The use of Artrosan is contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. The consumption of alcohol is also formally noted to increase the risk for serious gastrointestinal bleeding.

Documented Pharmacodynamic Interactions

Combinations with medications that interfere with hemostasis, such as anticoagulants (e.g., warfarin), antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), are documented to increase the overall risk of bleeding complications. Furthermore, Artrosan may diminish the antihypertensive and natriuretic effects of ACE Inhibitors, ARBs, Diuretics, and Beta-blockers.

Exposure Modification

• Increased Levels of Other Medicines: Artrosan can result in increased plasma concentrations of lithium and can competitively enhance the toxicity of methotrexate at high doses.
• Reduced Artrosan Exposure: Co-administration with cholestyramine is documented to significantly increase the clearance of meloxicam, resulting in a formally stated reduction in plasma exposure.

Population-Specific Notes

Regulatory information notes that the risk of renal function deterioration from interactions with ACE Inhibitors or ARBs is explicitly heightened in elderly patients or those who are volume-depleted or have existing renal impairment.

Molecular Mechanism: Inhibiting Prostaglandin Production

Artrosan, containing meloxicam, works by establishing a specific inhibitory interaction with the Cyclooxygenase enzyme ( COX), primarily targeting the COX-2 isoform. . This COX-2 enzyme is responsible for converting arachidonic acid into pro-inflammatory prostaglandins. By inhibiting COX-2, meloxicam modifies this early molecular step, leading to a substantial reduction in the synthesis and release of pro-inflammatory mediators, particularly PGE2, at sites of heightened physiological response.

---

Causal Chain: Modulation of Inflammatory and Nociceptive Signaling

The reduction of prostaglandins directly modulates overactive physiological responses, resulting in a reduced intensity of inflammatory and nociceptive signaling. The decreased concentration of PGE2 decreases localized vasodilation and edema formation, and prevents the sensitization of peripheral nociceptors (pain-sensing nerves) to other chemical irritants. This inhibition of the nociceptive pathway leads to a systemic physiological change that reduces the peripheral sensitization of nociceptors and modulates the hypothalamic thermal set point due to reduced PGE2 activity.

How to Use Artrosan: Official Administration Guidelines

Artrosan, which contains meloxicam, is associated with specific parameters detailing the route, dosage, and frequency. The medication is primarily available for oral intake (tablets or suspension) and for parenteral administration via intramuscular (IM) injection.

Dosing and Administration Patterns

The medication is administered once daily. For chronic conditions, the standard adult oral starting dose is 7.5 mg, which may be increased to a maximum of 15 mg once daily if required for symptomatic benefit. The total daily intake from all formulations must not exceed 15 mg. Oral tablets may generally be taken without regard to the timing of meals.

Administration Route	Official Usage Principle
Oral (Tablets/Suspension)	Used for long-term maintenance; taken once daily.
Intramuscular (IM)	Restricted to short-term initiation of treatment, typically a maximum of 2–3 days, before switching to the oral form.

Procedural and Population Constraints

The IM solution is for administration via a deep intramuscular injection only; it is not approved for intravenous use in this formulation. Dose adjustments apply for specific populations. For instance, the maximum daily oral dose is limited to 7.5 mg for patients with severe renal impairment on hemodialysis. Similarly, treatment for older adults and those with known risk factors is typically initiated at the lower 7.5 mg/day dose. If a dose is missed, the next dose is typically taken at the regularly scheduled time; two doses are not taken to compensate for the missed one.

Research evidence / Overview of studies for Artrosan

---

Evidence for Use in Chronic Joint Conditions

The core evidence base for Artrosan (meloxicam) includes Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms related to physical discomfort and functional limitations change over time in adults with chronic inflammatory conditions. Researchers frequently compared Artrosan to an inactive treatment (placebo) or to other similar medications already available.

Research Base for Osteoarthritis (OA)

For conditions marked by functional limitations such as Osteoarthritis, research examined Artrosan through short-term RCTs, typically lasting 8 to 12 weeks. The main research focus was on outcomes related to physical discomfort, such as pain intensity (measured using rating scales) and functional status (tracked using validated indices). Findings describe measurements of change in pain and function compared to baseline or a comparator group over the study period. Studies are primarily focused on short-term symptom management, and there is limited information for long-term outcomes that track joint health or function over many years.

Research Base for Rheumatoid Arthritis (RA)

Artrosan was evaluated in studies of adults diagnosed with Rheumatoid Arthritis. Researchers monitored outcomes related to systemic or functional imbalance using established, composite disease activity scores. Trial reports documented measurements of change in joint swelling, tenderness, and morning stiffness. Evidence contributes to understanding symptom patterns, but the research has explored symptom management rather than focusing on underlying disease progression.

---

Evidence for Use in Ankylosing Spondylitis and Acute Pain

Evidence in Ankylosing Spondylitis (AS)

For conditions associated with acute or disruptive episodes such as Ankylosing Spondylitis, Artrosan was evaluated in studies examining outcomes related to physical discomfort and functional limitations in the spine. Data show patterns related to how these symptoms evolved in the observed populations over the study period. However, research exploring long-term functional preservation is limited and still emerging.

Evidence for Acute Pain Relief

Research has explored the use of Artrosan for pain that follows surgical procedures, using ultra-short-term follow-up periods (often just 24 to 48 hours). Both the oral tablet and the solution for injection were evaluated in these settings. Primary outcomes included pain intensity and the consumption of supplemental pain medication. These results apply only to the populations studied in these immediate settings and provide no insight into the use of the injectable form for chronic conditions.

---

Study Limitations and Remaining Research Uncertainty

The research provides context but not individual predictions about how Artrosan may work for every person. The existing evidence has several important limitations. First, the research focus is heavily centered on symptom management rather than tracking whether the medicine alters the course of the underlying inflammatory disease. Second, while research describes patterns, the evidence quality varies across studies, and the duration of follow-up in the most rigorous trials was generally short. These factors mean the evidence highlights what is known—and what is still uncertain—about this medicine.

Key Studies & References

1. DailyMed Label for Meloxicam (NIH/NLM)
2. Public Assessment Report: Scientific Discussion for Meloxicam 7.5 mg and 15 mg Tablets (Covers OA, RA, AS)

Common questions about Artrosan (FAQ)

Q: What is Artrosan used for?

According to official product information, Artrosan is used for symptomatic treatment of pain and inflammation associated with osteoarthritis, which is a condition affecting the joints. It is typically prescribed to help relieve the short-term symptoms of joint disease. This medication belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Can I take Artrosan if I have asthma or breathing difficulties?

Regulatory documents state that Artrosan is contraindicated, or should not be used, in people with asthma or breathing difficulties that have been previously triggered by taking other NSAIDs or aspirin. This is because it could potentially worsen existing breathing problems. A discussion of your full medical history with a healthcare professional is necessary before initiating treatment.

---

Q: Is Artrosan safe to use if I have had a heart attack or stroke?

Official information indicates that Artrosan is not recommended for patients with established ischaemic heart disease (reduced blood supply to the heart) or cerebrovascular disease (conditions affecting blood vessels in the brain), which includes those who have recently had a heart attack or stroke. Use in these patients requires careful consideration by a healthcare professional due to potential risks. Official information generally emphasizes that when used, the treatment should employ the lowest effective dose for the shortest possible duration.

---

Q: What does 'symptomatic treatment' mean for Artrosan?

Symptomatic treatment means that Artrosan is used to relieve the signs and symptoms of your condition, specifically pain and inflammation. According to regulatory sources, this medication does not cure the underlying joint disease (osteoarthritis) but is intended only to manage the discomfort. By reducing pain, the medication aims to help manage the overall discomfort associated with the condition.

How to Store and Dispose of Artrosan (Meloxicam)

Artrosan (meloxicam) must be stored according to official regulatory specifications to maintain its stability. The medication must be kept at a Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). Storage areas must avoid excessive heat and moisture, meaning the medicine should not be kept in a bathroom.

Storage and Handling Rules

• Protection: The product must be stored out of the sight and reach of children in its original container, which should be kept tightly closed.
• Disposal: Unused or expired meloxicam should be disposed of through a medicine take-back program. If a program is unavailable, mix the medicine with an unappealing substance, seal it in a bag, and place it in the household trash. The medication should not be flushed down the toilet.